Английская Википедия:CPP-115
Шаблон:Short description Шаблон:Infobox drug
CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2][3] and Tourette syndrome.[4]
CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]
History
CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6][7]
CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]
As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]
References
Шаблон:Nervous-system-drug-stub
